Jubilant Ingrevia Q1 FY27 Earnings Call Transcript: Revenue Jumps 25% as Specialty Chemicals and Nutrition Drive Growth

What Happened ?

key details

Specialty Chemicals Continue to Drive Profitability:

• Specialty Chemicals revenue increased to ₹533 crore, growing 11% YoY and 3% QoQ.
• EBITDA reached ₹139 crore, with a healthy 26% EBITDA margin.
• Fine Chemicals and CDMO businesses continued to report strong growth supported by higher volumes and improved pricing.
• Pyridine and picoline volumes remained stable, while cost optimisation initiatives helped offset pricing pressure in base pyridine products.
• Higher-value CDMO and fine chemical products continued to improve the overall product mix. 

Note:

• Management expects Specialty Chemicals to remain one of the primary earnings drivers during FY27.

CDMO Pipeline Expands with Strong Commercial Momentum:

• The CDMO and Fine Chemicals pipeline now includes 100+ molecules with a peak revenue potential exceeding ₹3,500 crore.
• Confirmed commercial molecules increased to 25+, up from 20 in the previous quarter.
• Five new molecules were added during Q1 across:
  • Pharmaceuticals
  • Personal Care
  • Semiconductors
• The company expects confirmed molecules to contribute an increasing share of future revenues as commercialization progresses.
• Management indicated that several existing CDMO molecules are expected to witness higher customer volumes during FY27.

Note:

• The expanding CDMO pipeline provides long-term visibility for high-margin specialty chemical growth.

Nutrition Business Delivers Highest EBITDA in Three Years:

• Nutrition & Health revenue grew 36% YoY to ₹243 crore.
• EBITDA increased 45% YoY to ₹36 crore, the highest level in the last three years.
• Niacinamide volumes and pricing improved across food and cosmetic applications.
• Choline chloride and CBT pricing also strengthened during the quarter.
• Animal Nutrition benefited from significant improvement in Vitamin B3 pricing and healthy export demand.
• The recently commissioned niacinamide facility has already reached more than 50% utilisation, with management targeting over 70% utilisation by the end of FY27. 

Note:

• Nutrition remains one of the company’s fastest-growing and highest-margin businesses.

Chemical Intermediates Rebound Strongly:

• Segment revenue increased 38% YoY to ₹524 crore.
• EBITDA surged 240% YoY to ₹57 crore.
• Strong demand recovery and higher product prices supported the turnaround.
• Rising raw material and logistics costs were successfully passed on to customers through improved realizations.
• Management indicated that current pricing trends continue to remain supportive during Q2 FY27. 

Note:

• Although Chemical Intermediates remain cyclical, improving industry conditions have significantly strengthened profitability.

FY27 Outlook Remains Positive:

• Management reiterated its FY27 EBITDA guidance of ₹750–800 crore.
• Revenue and EBITDA are expected to improve sequentially through the remaining quarters.
• Growth is expected to be driven primarily by:
  • Specialty Chemicals
  • Nutrition & Health
  • CDMO
  • Fine Chemicals
• The new multipurpose manufacturing plant remains on schedule for commissioning by the end of the current calendar year.
• Lean initiatives are expected to deliver approximately ₹100 crore in cost savings during FY27. 

Note:

• Management remains optimistic that the Pinnacle Strategy will continue to accelerate earnings growth while strengthening the company’s specialty chemicals portfolio.

Management Outlook:

• Pharmaceuticals, nutrition and specialty chemicals are expected to remain the key growth engines during FY27.
• Higher utilisation of the niacinamide plant and continued expansion of the CDMO pipeline should support margin improvement.
• Customer engagement remains strong across electronics, semiconductors, cosmetics and personal care.
• The company continues evaluating acquisition opportunities in high-growth specialty chemical segments.
• Management expects sequential improvement in both revenue and EBITDA while maintaining disciplined capital allocation and operational excellence.

Risk Analysis

Summary:

• Jubilant Ingrevia delivered a strong Q1 FY27 with broad-based growth across Specialty Chemicals, Nutrition and Chemical Intermediates, supported by improving pricing, healthy demand and expanding CDMO opportunities. However, the company continues to operate in a cyclical chemicals industry where profitability depends on raw material prices, customer demand, execution of large CDMO contracts and global supply chain conditions. Management remains optimistic about sequential growth but acknowledged that market volatility could affect near-term performance.

Key Risks:

• Delays or lower-than-expected volumes under the large agro CDMO contract could affect revenue growth, although management stated that EBITDA expectations remain protected.
• Volatility in raw material prices and crude oil could impact margins if cost increases cannot be fully passed on to customers.
• Pricing pressure in commodity pyridine products due to excess capacity in China may continue.
• Chemical Intermediates remain cyclical and are sensitive to changes in global demand and product pricing.
• Weak recovery in agrochemicals or slower commercialization of new CDMO molecules could delay expected earnings growth.
• Geopolitical tensions and supply chain disruptions may increase logistics and input costs. 

Worst Case:

• If CDMO order execution slows materially, specialty chemical demand weakens and raw material costs rise without corresponding price increases, Jubilant Ingrevia could face slower revenue growth, margin compression and delayed achievement of its long-term growth targets. Continued weakness in agrochemical markets or prolonged pricing pressure in commodity chemicals could further impact profitability.

Risk Level: Medium

Company Commentary

• Management reaffirmed its FY27 EBITDA guidance of ₹750–800 crore.
• Revenue and EBITDA are expected to improve sequentially over the remaining quarters of FY27.
• The Pinnacle Strategy continues to strengthen the company’s Specialty Chemicals, Nutrition and CDMO businesses.
• The new multipurpose manufacturing plant remains on schedule for commissioning by the end of the current calendar year.
• Management remains confident that the expanding CDMO pipeline, higher utilisation of new capacities and improving market conditions will support long-term earnings growth.